A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00144144|
Recruitment Status : Unknown
Verified July 2006 by Advanced-J.
Recruitment status was: Active, not recruiting
First Posted : September 5, 2005
Last Update Posted : July 14, 2006
|Condition or disease||Intervention/treatment||Phase|
|Hypertension Diabetes Mellitus, Type 2||Drug: Angiotensin II receptor antagonists, Calcium channel blocker||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Controlled Study on Calcium Channel Blocker Versus Angiotensin II Antagonists in the Hypertensive Patients With Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure With Angiotension II Antagonists|
|Study Start Date :||September 2004|
|Study Completion Date :||September 2008|
- Changes in blood pressure level at home after getting up.
- The rate of the blood pressure levels at home after getting up, which effected the target levels (systolic blood pressure < 125 mm Hg, diastolic blood pressure < 80 mm Hg).
- Adverse events, adverse drug reactions
- Clinical laboratory data
- Changes in blood pressure levels measured on an outpatient basis.
- The rate of the blood pressure levels measured on an outpatient basis, which effected the standard levels (systolic blood pressure level <130 mm Hg, diastolic blood pressure level < 80 mm Hg).
- Changes in blood pressure levels measured at home before going to bed· Changes in IMT of the cervical artery
- Changes in PWV· Changes in echocardiographic findings
- Changes in urinary albumin level
- Changes in BNP· Changes in hs-CRP· Medical cost-effectiveness
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00144144
|Dept. of Clinical Immunology, Clinical Bioinformatics Research Unit, Graduate School of Medicine, the University of Tokyo|
|Hongo, Bunkyo-ku, Tokyo, Japan, 113-8655|
|Principal Investigator:||Ryuzo Kawamori, M.D.||Juntendo University School of Medicine, Dept. of Endocrinology and Metabolism|